Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Leukemia, Myeloid, Acute 96Leukemia 90Myelodysplastic Syndromes 83Precursor Cell Lymphoblastic Leukemia-Lymphoma 71Lymphoma, Non-Hodgkin 62Lymphoma 60Multiple Myeloma 53Hodgkin Disease 48Leukemia, Lymphocytic, Chronic, B-Cell 46Myeloproliferative Disorders 41Leukemia, Myeloid, Chronic-Phase 41Leukemia, Myeloid, Accelerated Phase 37Congenital Abnormalities 37Lymphoma, Large B-Cell, Diffuse 35Neoplasms, Plasma Cell 34Lymphoma, Follicular 34Leukemia, Myelomonocytic, Chronic 34Burkitt Lymphoma 33Anemia, Refractory, with Excess of Blasts 32Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 29Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Lymphoma, Large-Cell, Immunoblastic 28Blast Crisis 26Myelodysplastic-Myeloproliferative Diseases 25Recurrence 24Primary Myelofibrosis 24Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 24Hematologic Neoplasms 24Dendritic Cell Sarcoma, Interdigitating 22

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Busulfan × Clear all
NCT00060255 2013-05-09

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Roswell Park Cancer Institute

Phase 2 Completed
451 enrolled
BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Testicular Germ Cell Tumor, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Recurrence, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating

NCT00007995 2013-02-04

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡